Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa). The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More
Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More
The European Commission has granted orphan designation to asedebart (Lu AG13909) to brain health biopharmaceutical company Lundbeck’s novel investigational anti-ACTH monoclonal antibody (mAb), for the treatment of Cushing’s syndrome of endogenous origin. Cushing’s syndrome of endogenous origin includes both ACTH-dependent and ACTH-independent forms. ACTH-dependent Cushing’s syndrome is a rare, serious endocrine… Read More
Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101. Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard’s approach is grounded… Read More
Kairos Pharma has shared interim safety data from its ongoing Phase I clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca’s Tagrisso) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The company says the data represent a pivotal milestone in its lead programme: resensitising patients… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More
A proof-of-concept study led by a scientist at the University of Florida suggests a monoclonal antibody that targets a master regulator of inflammation, called NAMPT, could offer much-needed treatment for acute respiratory distress syndrome (ARDS). In the study, a monoclonal antibody treatment called ALT-100 was used in… Read More
Susan Abushakra, MD, Chief Medical Officer at Alzheon, discusses the validity of the amyloid hypothesis in light of the recent Cochrane review that found no clinical benefit of anti-amyloid monoclonal antibodies. A Cochrane systematic review published in April 2026 by Nonino, et al. – examining 17 randomised… Read More
The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP). The NEJM-published data showed patients treated with mezagitamab achieved: … Read More
iBio has received approval to initiate a first-in-human clinical trial for its long-acting monoclonal antibody IBIO-600 in Australia. The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult… Read More
Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimisation for a monoclonal antibody cocktail. The therapy will target filovirus diseases, including Ebola virus (EBOV) and Sudan virus… Read More
A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More
A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More
DDW Editor Reece Armstrong speaks to Elke Bestel, Chief Medical Officer at Igyxos, about the… Read More
